Novartis (NVS) To Acquire The Medicines Company For $9.7B
Zacks Investment Research | Nov 24, 2019 09:43PM ET
Swiss pharma giant Novartis (NYSE:NVS) is the latest company to join the ongoing M&A wave in the pharma/biotech sector.
The company announced that it entered an agreement to acquire U.S.-based biopharmaceutical company, The Medicines Company (NASDAQ:MDCO) , for $85 per share in cash or a total valuation of $9.7 billion, and add a potentially transformational investigational cholesterol-lowering therapy.
Financial Terms of the Acquisition
Per the terms, the offer price represents a premium of approximately 41% over The Medicines Company’s 30-day (to November 22, 2019) volume-weighted average price of $60.33 and approximately 24% premium over the closing share price of $68.55 on Nov 22, which represented a fully diluted equity value of approximately $7.7 billion.
The transaction, expected to close in the first quarter of 2020, has been unanimously approved by the boards of both companies.
The acquisition is expected to modestly dilute core earnings per share.
Value of the Deal
The acquisition will add a potentially first-in-class siRNA inhibitor targeting PCSK9, inclisiran, to Novartis’ pipeline. The Medicines Company recently announced data from its late-stage program consisting of three phase III studies (ORION-9, 10 and 11) on inclisiran for the treatment of atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH). Inclisiran demonstrated potent and durable LDL-C reduction with an excellent safety and tolerability profile. The candidate’s twice-yearly dosing schedule allows administration during patients’ routine visits to their healthcare professionals and will likely improve patient adherence and sustain lower LDL-C levels.
Additionally, an ongoing clinical trial (ORION-4) will evaluate the cardiovascular morbidity and mortality benefits of inclisiran.
The Medicines Company expects to file regulatory submissions in the United States in the fourth quarter of 2019 and Europe in the first quarter of 2020. The Medicines Company has a partnership with Alnylam Pharmaceuticals for the development of PCSK9 inhibitor, inclisiran.
Our Take
The planned acquisition will add a promising candidate to Novartis’ cardiovascular portfolio, which includes Entresto. With regulatory applications planned shortly, inclisiran represents a near-term product launch opportunity and is expected to contribute to sales from 2021. The twice-yearly dosing schedule provides a great advantage to the candidate over the existing treatments in the market.
Though the targeted market holds significant potential, competition is stiff from the likes of Amgen’s (NASDAQ:AMGN) Repatha and Regeneron and Sanofi’s (NASDAQ:SNY) Praluent. While Praluent and Repatha are approved with once every two weeks or once a month dosing, inclisiran has been developed for twice-a-year dosing.
Shares of the company have gained 5.5% year to date compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.